Cytotoxic effects of celecoxib on Raji lymphoma cells correlate with aggravated endoplasmic reticulum stress but not with inhibition of cyclooxygenase-2

Leukemia Research

Volumn 34, Issue 2, 2010, Pages 250-253

  Chen, Szu Ting ^a   Thomas, Simmy ^b   Gaffney, Kevin J ^a   Louie, Stan G ^a   Petasis, Nicos A ^a   Schönthal, Axel H ^b  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

CHOP GADD153; Cyclooxygenase 2; Endoplasmic reticulum stress

Indexed keywords

2,5 DIMETHYLCELECOXIB; BORTEZOMIB; CELECOXIB; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; ROFECOXIB; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG MECHANISM; DRUG POTENCY; DRUG POTENTIATION; ENDOPLASMIC RETICULUM STRESS; ENZYME INHIBITION; HUMAN; HUMAN CELL; IN VITRO STUDY; LYMPHOMA CELL; PRIORITY JOURNAL; RAJI CELL;

BORONIC ACIDS; CELL DEATH; CELL LINE, TUMOR; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITORS; DRUG SYNERGISM; ENDOPLASMIC RETICULUM; HUMANS; LYMPHOMA; PYRAZINES; PYRAZOLES; STRESS, PHYSIOLOGICAL; SULFONAMIDES;

EID: 74849114527     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.leukres.2009.09.028     Document Type: Article

References (8)

1. Kashfi K., and Rigas B. Is COX-2 a 'collateral' target in cancer prevention?. Biochem Soc Trans 33 (2005) 724-727
2. Grösch S., Maier T.J., Schiffmann S., and Geisslinger G. Cyclooxygenase-2 (COX-2)-independent anticarcinogenic effects of selective COX-2 inhibitors. J Natl Cancer Inst 98 (2006) 736-747
3. Schönthal A.H. Direct non-cyclooxygenase-2 targets of celecoxib and their potential relevance for cancer therapy. Br J Cancer 97 (2007) 1465-1468
4. Pyrko P., Kardosh A., Liu Y.T., Soriano N., Xiong W., Chow R.H., et al. Calcium-activated ER stress as a major component of tumor cell death induced by 2,5-dimethyl-celecoxib (DMC), a non-coxib analog of celecoxib. Mol Cancer Ther 6 (2007) 1262-1275
5. Kardosh A., Wang W., Uddin J., Petasis N.A., Hofman F., Chen C.C., et al. Dimethyl-celecoxib (DMC), a derivative of celecoxib that lacks cyclooxygenase-2-inhibitory function, potently mimics the anti-tumor effects of celecoxib on Burkitt's lymphoma in vitro and in vivo. Cancer Biol Ther 4 (2005) 571-582
6. Wun T., McKnight H., and Tuscano J.M. Increased cyclooxygenase-2 (COX-2): a potential role in the pathogenesis of lymphoma. Leuk Res 28 (2004) 179-190
7. Phipps R.P., Ryan E., and Bernstein S.H. Inhibition of cyclooxygenase-2: a new targeted therapy for B-cell lymphoma?. Leuk Res 28 (2004) 109-111
8. Nawrocki S.T., Carew J.S., Dunner Jr. K., Boise L.H., Chiao P.J., Huang P., et al. Bortezomib inhibits PKR-like endoplasmic reticulum (ER) kinase and induces apoptosis via ER stress in human pancreatic cancer cells. Cancer Res 65 (2005) 11510-11519